193 results about "Pancreas Carcinoma" patented technology

The invention discloses a traditional Chinese medicine preparation for treating cancer, which is prepared by 103 types of bulk drugs such as solidago decurrens, Chinese sage herb, hypericum japonicumand the like. A preparation method of the traditional Chinese medicine preparation comprises the following steps: preparing the bulk drugs into water extract by a conventional method; using the prepared water extract for preparing oral solution by a traditional method; drying the obtained water extraction, then conducting grinding and sieving; taking the throughs for extracting powder, and using the extracted powder for preparing tablets, granules, electuaries or capsules by a traditional method. The preparation method also can be as follows: sieving out the dust of the bulk drugs, conductinggrinding and sieving, taking the throughs, conducting disinfection and sterilization to obtain raw powder, and using the raw powder for preparing tablets, granules, electuaries or capsules by a traditional method. With drugs mixed rationally, the traditional Chinese medicine preparation addresses both the symptoms and root causes of cancer. The bulk drugs are frequently-used common Chinese drugs,have low preparation cost and small side effect, and can effectively enhance own immunity, attack pathogen while do not damage body. The traditional Chinese medicine preparation can cure various typesof cancer, particularly lung cancer, stomach cancer, liver cancer, esophageal cancer, pancreatic cancer, cervical cancer and breast cancer.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

PCT No. PCT / US97 / 11564 Sec. 371 Date Apr. 14, 1999 Sec. 102(e) Date Apr. 14, 1999 PCT Filed Jul. 8, 1997 PCT Pub. No. WO98 / 01132 PCT Pub. Date Jan. 15, 1998The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma / glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.

The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

The invention features a method of inhibiting tumor growth and / or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and / or detecting the antigen-antibody complex.

The present invention relates to a novel gene, CaSm, that is highly expressed in cancer tissues and cell lines, especially pancreatic cancer. The full length cDNA of CaSm encodes a protein of 133 amino acids. The present invention further encompasses CaSm peptides, fusion proteins, host cell expression systems, antibodies to CaSm, antisense CaSm molecules, and compounds that modulate CaSm gene expression or CaSm activity. The present invention also encompasses methods for disease diagnosis, drug screening and the treatment of cancer. In particular, the combined use of a CaSm antagonist with a therapeutic agent to treat cancer is encompassed.

The invention discloses attenuated salmonella typhimurium and application of a genetically engineered bacterium of the attenuated salmonella typhimurium to preparation of medicines for treating pancreatic cancer. The attenuated salmonella typhimurium has tumor targeting and a remarkable inhibiting effect on pancreatic cancer cells; the genetically engineered bacterium constructed by the attenuated salmonella typhimurium and a plasmid also has tumor targeting; the attenuated salmonella typhimurium with the plasmid with a clonal L-methioninase gene can continuously express L-methioninase on a tumor tissue to consume methionine and other nutrient substances to cause undernourishment and slow growth of tumor cells; therefore, both the attenuated salmonella typhimurium and the genetically engineered bacterium can be used for preparing the medicines for treating the pancreatic cancer.

The invention discloses PNA, probe and primer for testing K-ras genetic mutation, and a method for quantitatively testing the K-ras genetic mutation in real time by the PNA, the probe and the primer. The PNA is hybridized with the 12th codon and / or the 13th codon in the first exon of wild K-ras gene; and the PNA is combined with real-time quantitative PCR to quantitatively test the mutation amount of the K-ras gene in real time. The method has the advantages of simple and convenient operation, high sensitivity and high specificity, and can be applied to early auxiliary diagnosis for pancreatic cancer and other diseases.

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.

An endoscopic cryoablation apparatus for the ablation of unwanted tissues is disclosed. A method of utilizing the apparatus for ablating pancreatic cancer, gastrointestinal cancers, or other undesired tissue is also incorporated. The apparatus provides a cryoprobe needle tip covered by an outer sheath at a distal end of a catheter shaft such that the distal end includes a defined ablation zone. As implemented, the cryocatheter can be utilized alone or in combination with and endoscopic ultrasound. A moveable handle attached to the outer sheath is configured such that the handle retracts and protracts the outer sheath to expose and cover, respectively, the cryoprobe needle tip.

The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.

A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.

The invention discloses a kit for detecting DNA mismatch repair systems and application thereof; the kit comprises an amplifying system which comprises PCR (polymerase chain reaction) primer mixed liquid and PCR reaction liquid; the PCR primer mixed liquid contains microsatellite sites. The microsatellite sites in the kit are higher in sensitivity and accuracy and are suitable for detecting different cancers, such as colorectal cancer, endometrial cancer, gastric cancer, pancreatic cancer, lung cancer and breast cancer. The kit with microsatellite site for detecting DNA mismatch repair systems is better in repeatability, is suitable for detecting multiple microsatellite sites at the same time, and has improved detection efficiency.

The invention discloses a quantitative detection method of K-ras gene mutation, comprising the following steps: a PNA which is hybridized with a twelfth and / or thirteenth codon in a first exon of a wild-typed K-ras gene is designed; SYBR-RT-PCR quantitative detection is carried out to the mutant-typed and wild-typed standard products with known copy numbers respectively with the PNA for obtainingstandard and melting curves; SYBR-RT-PCR quantitative detection is carried out to the sample nucleic acid to be detected with the PNA; and after the sample nucleic acid to be detected is judged to bewild type or mutant type or mutant / wild hybrid type according to the melting curve, the K-ras gene mutation quantity of the sample nucleic acid to be detected is obtained according to the standard curve. The method of the invention has simple operation, high sensitivity and high specificity, and can be applied to early auxiliary diagnosis on diseases such as pancreatic cancer, etc.

The invention relates to a computer-aided method for distinguishing the ultrasound endoscope image of pancreatic cancer, providing a method for extracting and classifying the textural features of the ultrasound endoscope image of pancreatic cancer. The computer-aided method can be used for the computer-aided analysis of the ultrasound endoscope image of pancreatic cancer. 9 general classes which totally comprise 69 textural features are extracted from the ultrasound endoscope image of pancreatic cancer by a digital image processing algorithm. Class spacing is adopted to serve as a separability criterion to preliminarily screen the features; then, a chronological progress search algorithm is used for further screening the features; and the features are classified by a support vector machine. The method is realized by extracting the textural features of the ultrasound endoscope image via the classifier, various objective quantized diagnostic indexes and a method for correctly describing and explaining the ultrasound endoscope image are built, and the accuracy on the ultrasound endoscope early diagnosis of the pancreatic cancer is improved.

The present invention relates to a traditional Chinese medicine which is used for the treatment of cancers, in particular to a Chinese traditional patent medicine for treating lung cancer, cervical cancer, liver cancer, breast cancer, pancreatic cancer and malignant lymphoma. The present invention is characterized in that the present invention includes the raw materials with the following mix ratio by weight: 20 to 40 parts of honeycomb, 15 to 25 parts of oldworld arrowhead corm, 20 to 40 parts of hiraute shiny bugleweed herb, 30 to 50 parts of dahurian patrinia herb, 10 to 20 parts of gecko, 10 to 20 parts of pillbug, 30 to 50 parts of spreading hedyotis herb, 30 to 50 parts of common andrographis herb, 30 to 50 parts of barbed skullcap herb, 20 to 40 parts of common selfheal fruit-spike, 10 to 20 parts of Chinese thorowax root, 10 to 20 parts of figwort root and 10 to 20 parts of ginseng. The present invention has the effects of clearing heat, removing toxicity, promoting blood circulation, removing blood stasis, relieving swelling, resolving hard mass, benefiting qi and easing pain, which is applicable to the treatment of the patients with various mid-advanced tumors; the present invention can alleviate the clinical symptoms of the tumor patients, improve the cellular immune function of the patients, delay the development and the transfer of the cancers, improve the quality of life of the patients and prolong the survival period.

The invention provides a traditional Chinese medicine composition for treating the pancreatic cancer and a preparation method of the traditional Chinese medicine composition. The medicinal raw materials of the traditional Chinese medicine composition are as follows: herba sarcandrae, zaocys dhumnade, scutellariae barbatae, Chinese lobelia, oldenlandia diffusa, taraxacum mongolicum, herba violae, herba patriniae, flos lonicerae, fructus forsythiae, radix glycyrrhiza, herba lophatheri, herba artemisiae scopariae, codonopsis pilosula, fructus gardeniae, rheum officinale, semen coicis, caulis sargentodoxae, fructus mume, borneol, christina loosestrife herb, polyporus umbellatus, fructus galangae, radix curcumae longae, rhizoma acori graminei, fructus lycii, rhizoma belamcandae, radix paeoniae rubra and radix trichosanthis. The traditional Chinese medicine composition provided by the invention can be separately utilized or matched up with radiotherapy and chemotherapy, and have the effects of reducing the lumps in a short period and effectively controlling the metastatic spread of cancer cells; and moreover, the traditional Chinese medicine composition is capable of strengthening the immunologic function of the organisms so as to achieve the aims of inhibiting the growth of the cancer cells, being free of side effects simultaneously, enhancing the immunity of the organisms while treating and resisting the cancers, alleviating the pain of the patients, stabilizing the state of the illness, prolonging the life cycle and increasing the proportion of clinically treating the patients.

The invention relates to L-alanine-(14-oridonin) ester trifluoroacetate as well as a preparation method and application thereof. The preparation method of the compound comprises the following steps of: by taking oridonin (II) as a starting material, generating 14-position esterification reaction with N-BOC-L-alanine in the presence of DCC to obtain N-BOC-L-alanine oridonin ester (III), removing a BOC protective group in trifluoroacetic acid, and salt-forming to obtain L-alanine-(14-oridonin) ester trifluoroacetate (I). The compound can be applied to clinic very well, and is used for treating esophagus cancer, gastric cancer, primary liver cancer, pancreatic cancer, cardia cancer, colorectal cancer, bladder cancer, breast cancer, acute myelogenous leukemia, and the like.

A sustained release implant includes 0.1%-50% (w / w) nilotinib, 50-99% sustained release excipients and 0-15% sustained release moderator. Sustained release excipients are mainly one or combination of poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co- phosphoric acid propyl), polylactic acid, the copolymer of polylactic acid and hydroxyacetic acid and polifeprosan; sustained release moderator is one or combination of mannitol, sorbic alcohol and chondroitin; sustained release implant applied in local tumor can slowly release nilotinib onto local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction; the invention not only reduces overall toxic reaction of nilotinib, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy. The implant can be used for treating solid tumors including lung cancer, esophageal carcinoma, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic carcinoma, pancreatic cancer, bladder carcinoma, cerebroma, and colorectal cancer.

The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.

The invention discloses a composition with an effect of preventing and treating cancers. The composition is mainly prepared from the following Chinese herbal medicines in percentage by mass: 20 to 85 percent of airpotato yam rhizome and 15 to 80 percent of Chinese angelica. The Chinese medicinal composition has the effect of preventing and treating the cancers, can eliminate the limit that liver injury is easily induced by chemotherapeutic medicinal medicines, is suitable for treating various cancers such as liver cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, ovarian cancer, prostate cancer, esophagus cancer, pancreatic cancer, colon cancer, colorectal cancer, skin cancer, thyroid cancer, cervical carcinoma, leukemia and the like, can be used for preparing anti-cancer medicaments, realizes the application of the airpotato yam rhizome and Chinese angelica compositions to the preparation of medicaments for treating the cancers, develops the application range and the medicinal value of the airpotato yam rhizome and the Chinese angelica and makes creative contribution to the development of traditional Chinese medicine.

Human Colon Specific Polynucleotides (DNA and RNA), Polypeptides, and Antibodies, as well as methods for using and producing such polynucleotides, polypeptides, and antibodies are disclosed. More particularly, methods are disclosed for utilizing such polynucleotides, polypeptides, and antibodies to detect, diagnose, prevent, treat, and / or ameliorate cancer (particularly gastrointestinal tract cancers such as colon and pancreatic cancer). Also disclosed are compositions and methods for targeting and destroying cancer cells (particularly gastrointestinal tract cancers such as colon and pancreatic cancer) via the Colon Specific Protein and / or via the Colon Specific Protein Receptor. Moreover, methods of screening for antagonists and binding partners of the Colon Specific Protein and therapeutic uses of such antagonists and binding partners are also disclosed.

The invention belongs to the technical field of biomedicine. Based on the fact that the abnormal methylation of genes are involved in the generation and development of tumors, the invention aims to overcome the defects of a methylation sensitive restriction enzyme method, a bisulfite sequencing method and a methylation specificity PCR (Polymerase Chain Reaction) method, and provide a methylation quantitative detection method of the PCDH8 (Protocadherin-8) gene, with simple and convenient operation and high sensitivity. The detection method comprises the steps of: taking pancreatic cancer tissues, extracting DNA to prepare a standard curve sample of ACTB (Actin, Beta), and preparing a standard curve sample of PCDH8; extracting the DNA of a tissue to be detected, carrying out chemical decoration, designing a methylation primer and a probe for a CPG island in a human PCDH8 gene promoter area, and designing a BSP primer and a probe for a CPG island in a human reference gene ACTB promoter area, carrying out real-time quantitative PCR on the DNA subjected to the sulfite treatment by using a Taqman-MGB real-time quantitative PCR method, and calculating out a quantitative value on the methylation degree of a PCDH8 gene. The method has the advantages of rapidness, correctness and high sensitivity.

The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.

The invention discloses a new application of cucurbitacins and drug composition to treat pancreatic cancer in the medical technical domain, which is characterized by the following: adopting cucurbitacins and drug composition as raw material to prepare multiple kinds of agent, such as tablet, powder medicine, capsule, particle, turbid liquor, syrup, oral liquor, chrisma, paster and injection; fitting for giving drug individually or integrally to treat low leucocyte of pancreatic cancer and tumour patient due to radiotherapy; setting the drug supplying content at 0. 001mg / kg-1mg / kg for mouse, 0. 1mg-5mg / d for health people with optimum content at 0. 01mg / kg-0. 5mg / kg for mouse, 0. 3mg-3mg / d for health people every 1-4 times one day.

The invention provides an anticancer traditional Chinese medicine composition, belonging to the technical field of medicines. The traditional Chinese medicine composition comprises bezoar, sweet wormwood herb, musk, root of China creeper and all-grass of nerved twayblade. The traditional Chinese medicine composition has the beneficial effects that through a reasonable ratio of the five medicinal raw materials, the traditional Chinese medicine composition has synergetic effects and the double effects of directly inhibiting cancer cell growth and proliferation and enhancing the immune function; through clinical research trials, the traditional Chinese medicine composition can selectively inhibit and kill cancer cell proliferation to achieve the anticancer effect, can also promote differentiation of T and B lymphocytes and activate NK cells to enhance the body immunity, has quick treatment effects on cancers, does not have toxic or side effect, has a wide anticancer spectrum, especially has obvious curative effects on lung cancers, liver cancers, gastric cancers, intestinal cancers, lymph cancers, brain tumors, nasopharynx cancers, esophagus cancers, pancreatic cancers and cervical cancers, and does not have any impact on body cells, tissues, organ functions and hemogram in the medication period.